ロード中...
SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)
INTRODUCTION: The PI3K/Akt/mTOR pathway is activated in a majority of malignant pleural mesotheliomas (MPM). We evaluated the activity of everolimus, an oral mTOR inhibitor, in patients with unresectable MPM. METHODS: MPM patients who had received at least one but no more than two prior chemotherapy...
保存先:
| 出版年: | J Thorac Oncol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4304604/ https://ncbi.nlm.nih.gov/pubmed/25611229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000360 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|